Clinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
NCT06380816 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
- Lead sponsor
- Cancer Research UK
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 9, 2024
- Completion date
- November 30, 2029
- Enrollment
- 167 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumours, carcinoma, non-small-cell lung, carcinoma, renal cell (clear cell only), colorectal neoplasms, esophageal neoplasms, ovarian neoplasms, pancreatic neoplasms, squamous cell carcinoma of head and neck, stomach neoplasms (excluding gastrointestinal stromal tumors), triple negative breast neoplasms, uterine cervical neoplasms